BioSpace News Archive

IDTechEx Research predicts that the market for image recognition AI in medical diagnostics will exceed $3 billion by 2030.

Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that the required number of survival events for the pivotal Phase 3 INSPIRE has been reached.

Agenus Inc. (NASDAQ: AGEN), today announced it will provide an update on programs and plans and release its second quarter 2020 financial results before the market opens on Thursday, August 6, 2020.

Wisconsin Pharmacal Company, the official licensee of the Coleman brand of personal insect repellents, recently introduced its new Coleman Tick Protection Insect Repellent . The new EPA-registered personal insect repellent includes CDC-recommended 25% DEET to repel ticks that may carry Lyme disease, repelling ticks with an unscented

InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET. Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments. Following management’s fo

Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Catherine E. Owen as a new director. Catherine currently serves as Senior Vice President, Major Markets at Bristol-Myers Squibb, overseeing commercial operations for the business in 18 countries including Japan, Germany, France, and others across Europe. She jo

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that it will report its second quarter 2020 financial and operating results after the close of U

GenMark Diagnostics, Inc., a leading provider of automated, multiplex molecular diagnostic testing systems, announced that the company plans to participate in two upcoming investor conferences.

Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces financial results for the three months ended June 30, 2020.

Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the second quarter and six months ended June 30, 2020,